NYSE:PEN - Penumbra Stock Price, Forecast & News

Penumbra's stock was trading at $176.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PEN stock has decreased by 12.2% and is now trading at $155.37. View which stocks have been mosted impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Penumbra.

Penumbra is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Penumbra.

Penumbra Inc (NYSE:PEN) announced its quarterly earnings results on Tuesday, February, 25th. The company reported $0.22 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.18 by $0.04. The company had revenue of $145.26 million for the quarter, compared to the consensus estimate of $141.64 million. Penumbra had a return on equity of 7.72% and a net margin of 8.85%. View Penumbra's earnings history.

Penumbra updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $635-645 million, compared to the consensus revenue estimate of $651.96 million.

8 Wall Street analysts have issued twelve-month price targets for Penumbra's stock. Their forecasts range from $180.00 to $200.00. On average, they expect Penumbra's stock price to reach $191.50 in the next twelve months. This suggests a possible upside of 23.3% from the stock's current price. View analysts' price targets for Penumbra.

Press coverage about PEN stock has trended somewhat positive on Sunday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Penumbra earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutPenumbra.

Penumbra saw a decline in short interest in the month of March. As of March 13th, there was short interest totaling 3,402,700 shares, a decline of 13.2% from the February 27th total of 3,920,000 shares. Based on an average trading volume of 312,800 shares, the short-interest ratio is presently 10.9 days. Currently, 10.4% of the company's shares are short sold. View Penumbra's Current Options Chain.

Some companies that are related to Penumbra include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), Insulet (PODD), Hill-Rom (HRC), ABIOMED (ABMD), Novocure (NVCR), Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), ICU Medical (ICUI), Integra Lifesciences (IART), Nevro (NVRO), NuVasive (NUVA) and Irhythm Technologies (IRTC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Splunk (SPLK), AbbVie (ABBV), salesforce.com (CRM), Adobe (ADBE), Intuitive Surgical (ISRG), Paypal (PYPL) and DexCom (DXCM).

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Penumbra's stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), William Blair Investment Management LLC (3.49%), Baillie Gifford & Co. (2.79%), Alliancebernstein L.P. (2.54%), State Street Corp (2.32%) and Norges Bank (1.39%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View institutional ownership trends for Penumbra.

PEN stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Lord Abbett & CO. LLC, Alliancebernstein L.P., Baillie Gifford & Co., Russell Investments Group Ltd., Landscape Capital Management L.L.C., Point72 Asset Management L.P., and State Street Corp. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, and Thomas Wilder. View insider buying and selling activity for Penumbra.

PEN stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Barclays PLC, Goldman Sachs Group Inc., William Blair Investment Management LLC, Columbus Circle Investors, New York State Common Retirement Fund, Franklin Resources Inc., and Franklin Resources Inc.. View insider buying and selling activity for Penumbra.

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PEN stock can currently be purchased for approximately $155.37.

Penumbra has a market capitalization of $5.45 billion and generates $547.41 million in revenue each year. The company earns $48.46 million in net income (profit) each year or $0.98 on an earnings per share basis. Penumbra employs 2,700 workers across the globe. View additional information about Penumbra.

The official website for Penumbra is http://www.penumbrainc.com/.

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]